Written by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition.

An ideal source for hematologists, oncologists, and cancer researchers, this Second Edition features:

• a new eight-page color insert
• 200 color and black-and-white illustrations
• reworked content organized into three sections: MDS epidemiology and biology; diagnosis, classification, and prognosis; and MDS therapy
• thoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field

New topics in Myelodysplastic Syndrome include:

• del(5q) and 5q-syndrome, CMML, and MDS-MPD overlap syndrome
• the reborn DNA methyltransferase inhibiting nucleoside analogs
• the diagnosis of chronic myelomonocytic leukemia and other MDS cases with myeloproliferative features
• the role of mitochondria and the potential importance of iron overload in MDS
• global genomics approaches, such as cDNA expression arrays, array-based comparative genomic hybridization, and single nucleotide polymorphism array
• the role of abnormal mitochondrial ferritin accumulation and other mitochondrial metabolic anomalies in MD
• other disease-associated alterations, such as abnormalities of B lymphocyte populations in MD
• three recently approved drugs: azacitidine, lenalidomide, and decitabine

About the Author:

DAVID P. STEENSMA is a Consultant and Associate Professor of Medicine and Oncology at Mayo Clinic, Rochester, Minnesota, USA. Originally from the New York City suburbs, he received his M.D. from the Pritzker School of Medicine at the University of Chicago, Chicago, Illinois, USA. Dr. Steensma completed his clinical training in internal medicine, hematology and medical oncology at Mayo Clinic, and research training at the Weatherall Institute of Molecular Medicine in Oxford, England. His laboratory efforts focus on the molecular genetics of MDS, and he is also currently conducting several clinical trials aimed at improving outcomes and quality of life for patients with myelodysplastic syndromes (MDS) and various forms of anemia. He is a member of the North Central Cancer Treatment Group, Mayo Clinic Cancer Research Consortium, and the Eastern Cooperative Oncology Group Leukemia Committee.